On the filings, Merck (MRK) is the stronger stock right now — higher on our blended fundamentals-plus-verdict read, and we currently rate it HOLD.
Cheap on adjusted earnings and free cash flow, but flat revenue and a self-flagged 2028 patent cliff cap upside — a value hold, not a grower.
Cheap, high-quality cash machine — 28% margin, 35% ROE, its multiple — but revenue has stalled to +1.3%; own for income, not growth.
| Metric | PFE | MRK |
|---|---|---|
| Fundamentals score | 62 | 80 |
| Revenue growth (YoY) | -1.6% | +1.3% |
| Net income growth (YoY) | -3.2% | +6.6% |
| Net margin | 12.4% | 28.1% |
| Return on equity | 9.0% | 34.7% |
| ROIC (est.) | — | — |
| Liabilities / Equity | 1.40 | — |
| Piotroski F-score | 4 / 9 | 4 / 9 |
Bold green = the stronger figure. All rows derive from SEC XBRL filings — no market-price data on this page.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 19, 2026, 2:18 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 18, 2026, 7:22 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.